Filing Flows › NewAmsterdam Pharma Co N.V. (NAMS) › Q1 2025
NewAmsterdam Pharma Co N.V. (NAMS) Q1 2025 earnings results (first quarter 2025)
10-Q filed May 8, 2025
NewAmsterdam Pharma Co N.V. (NAMS) reported revenue of $3.0M for the first quarter 2025 (Q1 2025), +113% from a year earlier and -77% from the quarter before.
NewAmsterdam Pharma Co N.V., Q1 2025: revenue $3.0M (+113% year over year), net loss $39.5M, operating cash flow −$36.5M. The chart follows the revenue to costs, profit and cash.
| Q1 2025 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $3.0M | -77% | +113% |
| Operating profit | −$68.9M | — | — |
| Net earnings | −$39.5M | — | — |
| Operating cash flow | −$36.5M | — | — |
What changed
Revenue was $3.0M in Q1 2025, up 113% year over year and down 77% from the previous quarter.
Operating costs exceeded revenue by $68.9M, an operating margin of -2314.5%. Total costs grew 26% against revenue growth of 113%. The fastest-growing cost line was SG&A (+88%). The quarter ended with a net loss of $39.5M, narrower than the previous quarter's $92.2M loss. Non-operating items added $29.4M, -74% of pre-tax earnings, so the bottom line overstates operating performance.
Operating cash flow was −$36.5M. Non-cash charges added back $52K of depreciation and amortization and $15.2M of share-based compensation. Working capital and other items used $12.2M. Capital expenditures of $16K exceeded it, leaving free cash flow of −$36.5M.
Questions
What was NewAmsterdam Pharma Co N.V.'s revenue in the first quarter 2025?
NewAmsterdam Pharma Co N.V.